DAREONTM-9: A study to test how well different doses of BI 764532 are tolerated by people with small cell lung cancer when taken together with a single agent chemotherapy
1438-0009
Phase 1 other active
Quick answer
DAREONTM-9: A study to test how well different doses of BI 764532 are tolerated by people with small cell lung cancer when taken together with a single agent chemotherapy for relapsed/refractory extensive stage - small cell lung cancer (ES-SCLC) is a Phase 1 program (other) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim International GmbH
- Indication
- relapsed/refractory extensive stage - small cell lung cancer (ES-SCLC)
- Phase
- Phase 1
- Modality
- other
- Status
- active